Woeful Axovant starts axing staff, but departing CEO David Hung gets a $2.6M exit package/bonus
When the high-profile biotech exec David Hung signed on to helm Axovant $AXON back on April 10, the stock was still riding high at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
